|Bid||0.85 x 1200|
|Ask||0.95 x 800|
|Day's Range||0.90 - 0.95|
|52 Week Range||0.74 - 3.59|
|Beta (3Y Monthly)||3.93|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.50|
SAN DIEGO, Nov. 13, 2018 -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today provided a business update and announced financial.
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will host a conference call and live webcast at 8:30 a.m. Eastern Time on Tuesday, November 13, 2018, to provide a corporate update and to discuss the Company's financial results for the quarter ended September 30, 2018. To access the conference call via phone, dial (844) 831-3031 (domestic) or (443) 637-1284 (International). The conference ID number for the call is 5463588.
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will be presenting two late-breaking abstracts at the upcoming Association of Pharmaceutical Scientists (AAPS) meeting taking place November 4-7, 2018 in Washington D.C. The presentations will focus on recently completed studies demonstrating pharmacokinetics and tolerability of DARE-HRT1, a novel 17β- estradiol and progesterone intravaginal ring being developed for the treatment of vasomotor symptoms (VMS) commonly associated with the onset of menopause, and DARE-FRT1, a novel progesterone intravaginal ring (IVR) being developed for potential utilization in both in-vitro fertilization (IVF) and pre-term birth. “The compelling preclinical results demonstrate the ability to achieve target pharmacokinetic and tolerability objectives for both a single active IVR (DARE-FRT1) and dual active IVR (DARE-HRT1),” said Dr. David Friend, Daré’s Chief Scientific Officer.
SAN DIEGO, Oct. 23, 2018 -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair, Chief Business Officer,.
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s health-focused biopharmaceutical company, today announced it will be presenting scientific and technical details on its innovative intra-vaginal ring (IVR) technologies at the Partnership Opportunities in Drug Delivery (PODD) meeting being held on the 17th and 18th of October in Boston, Massachusetts. Daré’s Chief Scientific Officer, David Friend, PhD, will deliver a presentation entitled “Optimizing Drug Delivery Through Novel Intra-Vaginal Ring (IVR) Technology” on Wednesday, October 17th as part of the Track 2B sessions. “With eight potentially first-in-class women’s health products in development, we are committed to bring to market differentiated products designed to expand treatment options, improve outcomes, and facilitate convenience for women.
SAN DIEGO, Oct. 10, 2018 -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson, President.
Daré (DARE) continues to not only move their various development programs forward, but also continues to add promising candidates to their high-potential women’s health-focused pipeline. Relative to the latter, DARE’s most recent pipeline addition, CatSper, a potential first-in-kind contraceptive for both men and women, was announced in mid-July.
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Greg Matz to its board of directors. “Greg brings a broad and diverse skill set that includes organizational development and strategic planning for a global medical device company,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair, Chief Business Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6, 2018 at 12:05 p.m. Eastern Time. The company’s mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility.
NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Daré Bioscience (DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's reproductive health. Daré's lead product candidate, Ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies. On July 16th, the company announced that it has entered into an asset transfer agreement with Hydra Biosciences, Inc. for the transfer of all of Hydra's interest in certain intellectual property relating to Hydra's CatSper ion channel target portfolio.
LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on DERM sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Daré Bioscience Inc. (NASDAQ: DARE), Dermira Inc. (NASDAQ: DERM), Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA), and Egalet Corp. (NASDAQ: EGLT).
DARE is a pre-revenue, clinical-stage company engaged in the development of novel therapeutic technologies targeting unmet needs in women’s health. In July 2017, DARE obtained worldwide rights (licensed from ADVA-Tec) to Ovaprene, the company’s lead development program. While certain features of vaginal rings (including effectiveness, reversibility and convenience of monthly use) score high in consumer surveys and studies, hormone-related side-effects (including risk of serious cardiovascular events) are an oft-cited drawback of currently available options, such as NuvaRing (etonogestrel/ethinyl estradiol).
Daré Bioscience Inc’s (NASDAQ:DARE): Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women’s reproductive health products in the United States. The US$13.12M market-cap posted a lossRead More...
NEW YORK, NY / ACCESSWIRE / April 26, 2018 / Dare Biosicence shares were exploding on Wednesday after the women's biopharma company announced that it had entered into an exclusive worldwide license agreement for Juniper Pharmaceutical's Intravaginal Ring technology platform. Shares of Arcadia didn't have as good a day as Dare yesterday as news of the FDA reviewing the company's controversial Parkinson's drug Nuplazid surfaced. Daré Bioscience, Inc. shares closed up 56.69% on Wednesday with around 29 million shares traded.